Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Neoadjuvante Chemotherapie bei neu diagnostiziertem, fortgeschrittenem Ovarialkarzinom: ASCO-Leitlinien-Update
Journal of Clinical Oncology · 2025-03 · 43 (7) · 868-891
DOI: 10.1200/jco-24-02589 ↗Auf einen Blick
Das ASCO-Update gibt Empfehlungen zu NACT und primärer Zytoreduktionsoperation bei Stadium III-IV epithelialem Ovarial-, Tuben- oder primärem Peritonealkarzinom. Grundlage sind 61 Studien.
Fragestellung
Welche Empfehlungen gibt ASCO für NACT und primäre Zytoreduktionsoperation bei neu diagnostiziertem fortgeschrittenem epithelialem Ovarialkarzinom?
Methode
Leitlinien-Update mit aktualisierter systematischer Übersichtsarbeit durch ein multidisziplinäres Expert Panel.
Ergebnisse
Empfohlen werden u. a. gynäkologisch-onkologische Beurteilung, CA-125, CT von Abdomen/Becken und Thoraxbildgebung, genetische Testung, PCS bei hoher Chance auf Komplettzytoreduktion und NACT bei geringer Chance oder hohem perioperativem Risiko.
Schlussfolgerung der Autor:innen
Die Leitlinie beschreibt auf Basis der Literatur aktualisierte Empfehlungen zu Diagnostik und Therapie bei neu diagnostiziertem fortgeschrittenem epithelialem Ovarialkarzinom.
Kernaussagen
- 61 Studien bilden die Evidenzbasis.
- PCS bei hoher Wahrscheinlichkeit kompletter Zytoreduktion, sonst NACT.
- NACT: Platin-Taxan-Dublette; ICS nach ≤4 Zyklen bei Ansprechen oder Stabilität.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Leitlinie in der Zeitschrift Journal of Clinical Oncology, 2025-03. Verfasst von Stéphanie Gaillard und 16 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University, Baltimore, MD. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer (epithelial ovarian cancer [EOC]). METHODS A multidisciplinary Expert Panel convened and updated the systematic review. RESULTS Sixty-one studies form the evidence base. RECOMMENDATIONS Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included. All patients with EOC should be offered germline genetic and somatic testing at diagnosis. For patients with newly diagnosed advanced EOC who are fit for surgery and have a high likelihood of achieving complete cytoreduction, PCS is recommended. For patients fit for PCS but deemed unlikely to have complete cytoreduction, NACT is recommended. Patients with newly diagnosed advanced EOC and a high perioperative risk profile should receive NACT. Before NACT, patients should have histologic confirmation of invasive ovarian cancer. For NACT, a platinum-taxane doublet is recommended. Interval cytoreductive surgery (ICS) should be performed after ≤four cycles of NACT for patients with a response to chemotherapy or stable disease. For patients with stage III disease, good performance status, and adequate renal function treated with NACT, hyperthermic intraperitoneal chemotherapy may be offered during ICS. After ICS, chemotherapy should continue to complete a six-cycle treatment plan with the optional addition of bevacizumab. Patients with EOC should be offered US Food and Drug Administration–approved maintenance treatments. Patients with progressive disease on NACT should have diagnosis reconfirmed via tissue biopsy. Patients without previous comprehensive genetic or molecular profiling should be offered testing. Treatment options include alternative chemotherapy regimens, clinical trials, and/or initiation of end-of-life care. Additional information is available at www.asco.org/gynecologic-cancer-guidelines . This guideline has been endorsed by the Society of Gynecologic Oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Johns Hopkins University, Baltimore, MD.
- American Society of Clinical Oncology, Alexandria, VA.
- Mayo Clinic, Rochester, MN.
- Jefferson Health-Abington, Willow Grove, PA.
- LSU School of Medicine, New Orleans, LA.
- University of Minnesota Medical School & St Paul's Hospital Millennium Medical School, Minneapolis, MN.
ORCID-Profile: Stéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, William A Cliby, Rahel G Ghebre, Gregory M Gressel, Larissa A Meyer, Kathleen N Moore, Roisin E O'Cearbhaill, Ritu Salani, Willemien J van Driel, William P Tew
Förderung
- NCI NIH HHS
Zitieren
APA
Gaillard, S., Lacchetti, C., Armstrong, D. K., Cliby, W. A., Edelson, M. I., Garcia, A. A., Ghebre, R. G., Gressel, G. M., Lesnock, J. L., Meyer, L. A., Moore, K. N., O'Cearbhaill, R. E., Olawaiye, A. B., Salani, R., Sparacio, D., van Driel, W. J., & Tew, W. P. (2025). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 43(7), 868-891. https://doi.org/10.1200/jco-24-02589
Vancouver
Gaillard S, Lacchetti C, Armstrong DK, Cliby WA, Edelson MI, Garcia AA, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(7):868-891. doi:10.1200/jco-24-02589
BibTeX
@article{Gaillard2025,
author = {Gaillard, Stéphanie and Lacchetti, Christina and Armstrong, Deborah K and Cliby, William A and Edelson, Mitchell I and Garcia, Agustin A and Ghebre, Rahel G and Gressel, Gregory M and Lesnock, Jamie L and Meyer, Larissa A and Moore, Kathleen N and O'Cearbhaill, Roisin E and Olawaiye, Alexander B and Salani, Ritu and Sparacio, Dee and van Driel, Willemien J and Tew, William P},
title = {Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {7},
pages = {868--891},
doi = {10.1200/jco-24-02589}
}
EUVIMED